Scholars Central

Conference abstractPublished 20 Oct 2014

Placenta-derived mesenchymal stem cells and their secreted exosomes inhibit the self-renewal and stemness of glioma stem cells in vitro and in vivo

Authors: Chaya Brodie, Efrat Buchris, Susan Finnis, Simona Cazacu, Cunli Xiang, Hae Kyung Lee, Laila Poisson

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Mesenchymal stromal cells (MSCs) can be obtained from various sources, easily expanded in vitro for therapeutic applications and their safety and therapeutic impact have been demonstrated in various pre-clinical and clinical studies. MSCs have been shown to cross the blood brain barrier and migrate to sites of experimental GBM and can deliver cytotoxic compounds that exert antitumor effects. Here, we examined the effects of placenta-derived MSCs and their secreted exosomes on GSC stemness and oncogenic potential in vitro and in vivo. Placenta MSC-derived exosomes decreased the self-renewal, stemness markers, Nanog and Oct4 and the migration of these cells. Similarly, intracranial administration of the MSCs decreased the tumor volume of GSC-derived xenografts and prolonged animal survival. miRNA sequence analysis of placenta MSC-derived exosomes revealed a set of specific miRNAs that were downregulated in GSCs and that acted as tumor suppressors in these cells. We demonstrated delivery of some of these miRNAs to GSCs following treatments with MSC-derived exosomes. We further demonstrated that MSCs or exosomes that were loaded with exogenous miR-124 delivered high levels of this miRNA into glioma cells as detected by a novel quantitative miRNA reporter. Moreover, administration of placenta MSCs loaded with exogenous miR-124 exerted a strong inhibitory effect on GSC-derived xenograft growth. These results demonstrate that placenta-derived MSCs may have important clinical applications in stem cell-based glioma therapeutics. Moreover, these studies provide a novel approach for the targeted delivery of endogenous and exogenous anti-tumor miRNAs to glioma cells as a miRNA replacement therapy for GBM.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Chaya Brodie”
  • BylineArticles whose byline prints “Efrat Buchris”
  • BylineArticles whose byline prints “Susan Finnis”
  • BylineArticles whose byline prints “Simona Cazacu”
  • BylineArticles whose byline prints “Cunli Xiang”
  • BylineArticles whose byline prints “Hae Kyung Lee”
  • BylineArticles whose byline prints “Laila Poisson”